Skip to main content
Shahrokh Shariat, MD, Urology, New York, NY

ShahrokhFrancoisShariatMD

Urology New York, NY

Professor and Chairman, Department of Urology, Medical University of Vienna. Adjunct Professor of Urology and Medical Oncology at the Weill Cornell Medical College in New York, NY.

Dr. Shariat is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Shariat's full profile

Already have an account?

  • Office

    1275 York Ave
    Box 27
    New York, NY 10065
    Phone+1 469-363-8500

Education & Training

  • University of Texas Southwestern Medical Center
    University of Texas Southwestern Medical CenterResidency, Urology, 2003 - 2008
  • University of Vienna Faculty of Medicine
    University of Vienna Faculty of MedicineClass of 1998

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2010 - 2015

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-Based An...  
    Shahrokh Shariat, MD, European Urology
  • Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-Institutional Analysis  
    Shahrokh Shariat, Inderbir S Gill, European Urology
  • Comparison of Perioperative Outcomes Between Cytoreductive Radical Prostatectomy and Radical Prostatectomy for Nonmetastatic Prostate Cancer  
    Shahrokh Shariat, MD, European Urology
  • Join now to see all

Authored Content

  • A Urinary microRNA (miR) Signature for Diagnosis of Bladder CancerOctober 2018
  • A Urinary microRNA (miR) Signature for Diagnosis of Bladder CancerOctober 2018
  • Re: Docetaxel Versus Surveillance After Radical Prostatectomy for High-Risk Prostate Cancer: Results from the Prospective Randomised, Open-Label Phase 3 Scandinavian Prostate Cancer Group 12 TrialJuly 2018
  • Multi-Institutional Evaluation of the Prognostic Significance of EZH2 Expression in High-Grade Upper Tract Urothelial CarcinomaMay 2018
  • Multi-Institutional Evaluation of the Prognostic Significance of EZH2 Expression in High-Grade Upper Tract Urothelial CarcinomaMay 2018
  • A Systematic Review and Meta-Analysis of Lymphovascular Invasion in Patients Treated with Radical Cystectomy for Bladder Cancer☆April 2018
  • Accurate Prediction of Progression to Muscle-Invasive Disease in Patients with pT1G3 Bladder Cancer: A Clinical Decision-Making ToolMarch 2018
  • Conditional Analyses of Recurrence and Progression in Patients with TaG1 Non–Muscle-Invasive Bladder CancerMarch 2018
  • Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-Term Results from a Large, Multi-Institutional SeriesDecember 2017
  • The Effect of AB0 and Rhesus Blood Grouping Systems on Oncological Outcome in Patients Undergoing Radical Nephroureterectomy for Upper Tract Urothelial CarcinomaSeptember 2017
  • Join now to see all

Press Mentions

  • Variant Histology Worsens UTUC Outcomes, Study Finds
    Variant Histology Worsens UTUC Outcomes, Study FindsSeptember 5th, 2019
  • This Urologist Studies Adult Film Entertainers to Solve Sexual Dysfunction
    This Urologist Studies Adult Film Entertainers to Solve Sexual DysfunctionMay 17th, 2018
  • Tests May Predict Prostate Cancer Spread
    Tests May Predict Prostate Cancer SpreadJune 19th, 2008
  • Join now to see all